In a study involving 192 ovarian cancer patients, high levels of GPX4 were associated with resistance to platinum-based drugs, and siRNA-mediated knockdown of GPX4 reduced the resistance of ovarian cancer cells to these drugs (Wu et al., 2022). This evidence concerns the gene GPX4 and ovarian cancer.